Clinical Trials · NCT03287960
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 15
- Start date
- Jan 2018
- Locations
- 6 sites, 6 countries
- Primary endpoint
- Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)